Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

Overview

Journal Theranostics

Date 2017 May 23

PMID 28529637

Citations 349

Authors

Helen Ha

Bikash Debnath

Nouri Neamati

Affiliations

Soon will be listed here.

Abstract

The chemokine receptors CXCR1/2 and their ligand CXCL8 are essential for the activation and trafficking of inflammatory mediators as well as tumor progression and metastasis. The CXCL8-CXCR1/2 signaling axis is involved in the pathogenesis of several diseases including chronic obstructive pulmonary diseases (COPD), asthma, cystic fibrosis and cancer. Interaction between CXCL8 secreted by select cancer cells and CXCR1/2 in the tumor microenvironment is critical for cancer progression and metastasis. The CXCL8-CXCR1/2 axis may play an important role in tumor progression and metastasis by regulating cancer stem cell (CSC) proliferation and self-renewal. During the past two decades, several small-molecule CXCR1/2 inhibitors, CXCL8 releasing inhibitors, and neutralizing antibodies against CXCL8 and CXCR1/2 have been reported. As single agents, such inhibitors are expected to be efficacious in various inflammatory diseases. Several preclinical studies suggest that combination of CXCR1/2 inhibitors along with other targeted therapies, chemotherapies, and immunotherapy may be effective in treating select cancers. Currently, several of these inhibitors are in advanced clinical trials for COPD, asthma, and metastatic breast cancer. In this review, we provide a comprehensive analysis of the role of the CXCL8-CXCR1/2 axis and select genes co-expressed in this pathway in disease progression. We also discuss the latest progress in developing small-molecule drugs targeting this pathway.

Citing Articles

Integrative bioinformatics analysis of high-throughput sequencing and in vitro functional analysis leads to uncovering key hub genes in esophageal squamous cell carcinoma.

Shen F, Liu X, Ding F, Yu Z, Shi X, Cheng L Hereditas. 2025; 162(1):38.

PMID: 40087784 DOI: 10.1186/s41065-025-00398-4.

Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseases.

ODonnell C, Farelli J, Belaghzal H, Chen J, Beech L, Sullivan J Nat Commun. 2025; 16(1):2517.

PMID: 40082450 PMC: 11906599. DOI: 10.1038/s41467-025-57920-5.

Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα/CXCR2 Signaling Pathway in the Rat Spinal Cord.

Wang Y, Liu Q, Jiang Y, Mao L, Zoubaa M, Wang J CNS Neurosci Ther. 2025; 31(3):e70302.

PMID: 40079428 PMC: 11904945. DOI: 10.1111/cns.70302.

LncRNA-MALAT1 promotes triple-negative breast cancer progression and function as ceRNA to target REEP5 by sponging miR-106a-5p.

Yang Q, Fu Y, Feng W, Mao J, Xu N, Liu Q Eur J Med Res. 2025; 30(1):159.

PMID: 40059235 PMC: 11892299. DOI: 10.1186/s40001-025-02420-x.

Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies.

Hussain M, Goyal A, Goyal K, S R, Nellore J, Shahwan M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40047857 DOI: 10.1007/s00210-025-03970-x.

References

Cao D, Qian B, Zhang Z, Gao Y, Wu X . Chemokine receptor CXCR2 in dorsal root ganglion contributes to the maintenance of inflammatory pain. Brain Res Bull. 2016; 127:219-225. DOI: 10.1016/j.brainresbull.2016.09.016. View

Yang L, Liu Z, Wu R, Yao Q, Gu Z, Liu M . Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma. Onco Targets Ther. 2015; 8:3203-9. PMC: 4636088. DOI: 10.2147/OTT.S91626. View

Sharma B, Varney M, Saxena S, Wu L, Singh R . Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells. Cancer Lett. 2016; 372(2):192-200. PMC: 4821546. DOI: 10.1016/j.canlet.2015.12.011. View

Sukkurwala A, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M . Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ. 2013; 21(1):59-68. PMC: 3857625. DOI: 10.1038/cdd.2013.73. View

Paul T, Schumann C, Rudiger S, Boeck S, Heinemann V, Kachele V . Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer. 2014; 50(11):1855-63. DOI: 10.1016/j.ejca.2014.04.026. View

Schroder J, Mrowietz U, Morita E, Christophers E . Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol. 1987; 139(10):3474-83. View

Liu Y, Guo D, Tian L, Shang D, Zhao W, Li B . Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging. 2008; 31(2):175-88. DOI: 10.1016/j.neurobiolaging.2008.03.024. View

Devapatla B, Sharma A, Woo S . CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PLoS One. 2015; 10(9):e0139237. PMC: 4587670. DOI: 10.1371/journal.pone.0139237. View

Sharma B, Nannuru K, Varney M, Singh R . Host Cxcr2-dependent regulation of mammary tumor growth and metastasis. Clin Exp Metastasis. 2014; 32(1):65-72. PMC: 4821540. DOI: 10.1007/s10585-014-9691-0. View

10.

Jung J, Kang K, Kim J, Hong S, Park Y, Kim B . CXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, β-Catenin, and hTERT Activities. Stem Cells Dev. 2016; 25(13):1006-19. PMC: 4931345. DOI: 10.1089/scd.2015.0395. View

11.

Richardson R, Pridgen B, Haribabu B, Ali H, Snyderman R . Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation. J Biol Chem. 1998; 273(37):23830-6. DOI: 10.1074/jbc.273.37.23830. View

12.

Purohit A, Varney M, Rachagani S, Ouellette M, Batra S, Singh R . CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer. Oncotarget. 2016; 7(6):7280-96. PMC: 4872785. DOI: 10.18632/oncotarget.6906. View

13.

Fernando R, Castillo M, Litzinger M, Hamilton D, Palena C . IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011; 71(15):5296-306. PMC: 3148346. DOI: 10.1158/0008-5472.CAN-11-0156. View

14.

Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M . Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002; 72(5):847-55. View

15.

Singh J, Simoes B, Howell S, Farnie G, Clarke R . Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013; 15(4):210. PMC: 3978717. DOI: 10.1186/bcr3436. View

16.

Sunil Y, Ramadori G, Raddatzc D . Influence of NFkappaB inhibitors on IL-1beta-induced chemokine CXCL8 and -10 expression levels in intestinal epithelial cell lines: glucocorticoid ineffectiveness and paradoxical effect of PDTC. Int J Colorectal Dis. 2009; 25(3):323-33. PMC: 2814033. DOI: 10.1007/s00384-009-0847-3. View

17.

Soyza A, Pavord I, Elborn J, Smith D, Wray H, Puu M . A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015; 46(4):1021-32. DOI: 10.1183/13993003.00148-2015. View

18.

Hou Y, Wu Y, Farooq S, Guan X, Wang S, Liu Y . A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesis. Stem Cell Res. 2015; 14(2):133-43. DOI: 10.1016/j.scr.2014.12.001. View

19.

Perbellini O, Cioffi F, Malpeli G, Zanolin E, Lovato O, Scarpa A . Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 56(6):1897-900. DOI: 10.3109/10428194.2014.977889. View

20.

Lee L, Hellendall R, Wang Y, Haskill J, Mukaida N, Matsushima K . IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol. 2000; 164(5):2769-75. DOI: 10.4049/jimmunol.164.5.2769. View